Medication Monitor

Generic Name (Trade Name—Company)
February 12, 2018


Drug now approved for treatment of drug-resistant HABP and VABP

FDA approved ceftazidime/avibactam for patients aged 18 years or older for treatment of drug-resistant, hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by several susceptible gram-negative pathogens: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa and Haemophilus influenza.

Ceftazidime/avibactam was first approved in 2015 to treat adults with complicated intra-abdominal infections in combination with metronidazole.

In 2017, the drug was also approved to treat complicated urinary tract infections, including kidney infections.